



Virbac : the board of directors announces a capital reduction through cancellation of treasury shares.

Carros, France - Press release issued on September 13, 2024, after market close

During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders' meeting on June 20, 2023, decided to reduce the share capital of Virbac by canceling 67,340 treasury shares. These shares were acquired during 2023 under the share buyback program authorized by the same shareholders' meeting.

As of today, the share capital of Virbac amounts to €10,448,325, represented by 8,390,660 shares of €1.25, fully paid-up.

Following this capital reduction, the Dick family group holds 50.09% of the share capital of Virbac and 66.20% of its voting rights.

Information on the total number of voting rights and shares, as well as the shareholder structure, will be updated on the company's website corporate.virbac.com.

Focusing on animal health, from the beginning

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals' quality of life and to shaping together the future of animal health.



5,500
EMPLOYEES

+1.36% compared to 2022



SALES
SUBSIDIARIES
IN 35 COUNTRIES

59%
COMPANION
ANIMALS



1,247 MC

41%
FARM
ANIMALS

SALES
2023

6th WORLDWIDE

Ranking of veterinary drug manufacturers

+4.9% at constant exchange rates and scope compared to 2022



PRODUCTION
SITES
IN 11 COUNTRIES



R&D
CENTERS ON
5 CONTINENTS

Press contacts - Agence Libremullenlowe

Anne Da Silva Passos - a.dasilvapassos@libremullenlowe.fr - +33 7 60 53 99 28